Characterization of HER1 (c-erbB1) status in locally advanced breast cancer using fluorescence in situ hybridization and immunohistochemistry
Characterization of HER1 (c-erbB1) status in locally advanced breast cancer using fluorescence in situ hybridization and immunohistochemistry
复制标题
DOI：
10.1159/000084183
复制
发表时间：
2005-01-01
期刊：
影响因子：
--
通讯作者：
Solé, F
中科院分区：
文献类型：
--
作者：
Corzo, C;Tusquets, I;Solé, F
表皮生长因子受体（Epidermal growth factor receptor， EGFR）是由HER1原癌基因编码的一种170 kda的跨膜糖蛋白，位于7p12。这种受体与乳腺癌的发病机制有关。本研究的目的是利用荧光原位杂交（FISH）和免疫组织化学分析48例局部晚期乳腺癌（LABC）患者中HER1的状态。在新辅助化疗前，对LABC患者进行核心活检，并加工成石蜡块。然后使用FISH和HER1探针（Vysis, Downers Grove, illinois）进行活检。美国)。使用DakoCytomation（丹麦，A/S）和Zymed（旧金山，加州，美国）的两种不同的EGFR抗体进行免疫组织化学分析。尽管31%的病例表现为7号染色体异常，但未发现HER1扩增。仅有2例出现EGFR表达。LABC呈低水平EGFR表达。HER1扩增不存在于LABC，尽管7号染色体多体是一个常见的发现。版权所有(C) 2005 S. Karger AG，巴塞尔。
Epidermal growth factor receptor ( EGFR) is a 170-kDa transmembrane glycoprotein encoded by the HER1 protooncogene, located at 7p12. This receptor is related to the pathogenesis of breast cancer. The aim of this study was to analyze the status of HER1 using fluorescence in situ hybridization ( FISH) and immunohistochemistry in a series of 48 patients with locally advanced breast cancer (LABC). Before neoadjuvant chemotherapy, core biopsies were taken from patients with LABC and were processed into paraffin blocks. Biopsies were then studied using FISH with a HER1 probe (Vysis, Downers Grove, Ill., USA). They were also analyzed immunohistochemically using two different EGFR antibodies from DakoCytomation ( Denmark, A/S) and from Zymed ( San Francisco, Calif., USA). HER1 amplifications were not found, although 31% of the cases presented aneusomy of chromosome 7. Only 2 cases presented EGFR expression. LABC presented a low level of EGFR expression. HER1 amplification was not present in LABC, although the polysomy of chromosome 7 was a common finding. Copyright (C) 2005 S. Karger AG, Basel.